In vitro cytotoxic effect of stigmasterol derivatives against breast cancer cells.
Cytotoxicity
HCC70
MCF-12A
MCF-7
Stigmasterol
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
11 Sep 2023
11 Sep 2023
Historique:
received:
10
03
2023
accepted:
23
08
2023
medline:
13
9
2023
pubmed:
12
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Stigmasterol is an unsaturated phytosterol that belong to the class of tetracyclic steroids abundant in Rhoicissus tridentata. Stigmasterol is an important constituent since it has shown impressive pharmacological effects such as anti-osteoarthritis, anticancer, anti-diabetic, anti-inflammatory, antiparasitic, immunomodulatory, antifungal, antioxidant, antibacterial, and neuroprotective activities. Furthermore, due to the presence of π system and hydroxyl group, stigmasterol is readily derivatized through substitution and addition reactions, allowing for the synthesis of a wide variety of stigmasterol derivatives. Stigmasterol (1) isolated from Rhoicissus tridentata was used as starting material to yield eight bio-active derivatives (2-9) through acetylation, epoxidation, epoxide ring opening, oxidation, and dihydroxylation reactions. The structures of all the compounds were established using spectroscopic techniques, NMR, IR, MS, and melting points. The synthesized stigmasterol derivatives were screened for cytotoxicity against the hormone receptor-positive breast cancer (MCF-7), triple-negative breast cancer (HCC70), and non-tumorigenic mammary epithelial (MCF-12 A) cell lines using the resazurin assay. Eight stigmasterol derivatives were successfully synthesized namely; Stigmasterol acetate (2), Stigmasta-5,22-dien-3,7-dione (3), 5,6-Epoxystigmast-22-en-3β-ol (4), 5,6-Epoxystigmasta-3β,22,23-triol (5), Stigmastane-3β,5,6,22,23-pentol (6), Stigmasta-5-en-3,7-dion-22,23-diol (7), Stigmasta-3,7-dion-5,6,22,23-ol (8) and Stigmast-5-ene-3β,22,23-triol (9). This is the first report of Stigmasta-5-en-3,7-dion-22,23-diol (7) and Stigmasta-3,7-dion-5,6,22,23-ol (8). The synthesized stigmasterol analogues showed improved cytotoxic activity overall compared to the stigmasterol (1), which was not toxic to the three cell lines tested (EC Natural products from Rhoicissus tridentata and their derivatives exhibit a wide range of pharmacological activities, including anticancer activity. The results obtained from this study indicate that molecular modification of stigmasterol functional groups can generate structural analogues with improved anticancer activity. Stigmasterol derivatives have potential as candidates for novel anticancer drugs.
Sections du résumé
BACKGROUND
BACKGROUND
Stigmasterol is an unsaturated phytosterol that belong to the class of tetracyclic steroids abundant in Rhoicissus tridentata. Stigmasterol is an important constituent since it has shown impressive pharmacological effects such as anti-osteoarthritis, anticancer, anti-diabetic, anti-inflammatory, antiparasitic, immunomodulatory, antifungal, antioxidant, antibacterial, and neuroprotective activities. Furthermore, due to the presence of π system and hydroxyl group, stigmasterol is readily derivatized through substitution and addition reactions, allowing for the synthesis of a wide variety of stigmasterol derivatives.
METHODS
METHODS
Stigmasterol (1) isolated from Rhoicissus tridentata was used as starting material to yield eight bio-active derivatives (2-9) through acetylation, epoxidation, epoxide ring opening, oxidation, and dihydroxylation reactions. The structures of all the compounds were established using spectroscopic techniques, NMR, IR, MS, and melting points. The synthesized stigmasterol derivatives were screened for cytotoxicity against the hormone receptor-positive breast cancer (MCF-7), triple-negative breast cancer (HCC70), and non-tumorigenic mammary epithelial (MCF-12 A) cell lines using the resazurin assay.
RESULTS
RESULTS
Eight stigmasterol derivatives were successfully synthesized namely; Stigmasterol acetate (2), Stigmasta-5,22-dien-3,7-dione (3), 5,6-Epoxystigmast-22-en-3β-ol (4), 5,6-Epoxystigmasta-3β,22,23-triol (5), Stigmastane-3β,5,6,22,23-pentol (6), Stigmasta-5-en-3,7-dion-22,23-diol (7), Stigmasta-3,7-dion-5,6,22,23-ol (8) and Stigmast-5-ene-3β,22,23-triol (9). This is the first report of Stigmasta-5-en-3,7-dion-22,23-diol (7) and Stigmasta-3,7-dion-5,6,22,23-ol (8). The synthesized stigmasterol analogues showed improved cytotoxic activity overall compared to the stigmasterol (1), which was not toxic to the three cell lines tested (EC
CONCLUSION
CONCLUSIONS
Natural products from Rhoicissus tridentata and their derivatives exhibit a wide range of pharmacological activities, including anticancer activity. The results obtained from this study indicate that molecular modification of stigmasterol functional groups can generate structural analogues with improved anticancer activity. Stigmasterol derivatives have potential as candidates for novel anticancer drugs.
Identifiants
pubmed: 37697361
doi: 10.1186/s12906-023-04137-y
pii: 10.1186/s12906-023-04137-y
pmc: PMC10496295
doi:
Substances chimiques
pentol
25151-96-6
Stigmasterol
99WUK5D0Y8
Propylene Glycols
0
Antineoplastic Agents
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
316Subventions
Organisme : National Research Foundation
ID : 121119
Organisme : National Research Foundation
ID : 117898
Organisme : National Research Foundation
ID : TTK190403426633
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J BUON. 2018 Sep-Oct;23(5):1420-1425
pubmed: 30570868
PLoS One. 2017 Dec 12;12(12):e0189628
pubmed: 29232409
J Ethnopharmacol. 1999 Dec 15;68(1-3):267-74
pubmed: 10624887
Phytother Res. 2002 Mar;16 Suppl 1:S51-6
pubmed: 11933140
Invest New Drugs. 2012 Dec;30(6):2187-200
pubmed: 22249429
Osteoarthritis Cartilage. 2010 Jan;18(1):106-16
pubmed: 19786147
J Org Chem. 2005 Jun 10;70(12):4667-75
pubmed: 15932303
J Org Chem. 1977 Oct 28;42(22):3633-4
pubmed: 915584
Med Res Rev. 2016 Jan;36(1):32-91
pubmed: 26359649
Biochem Biophys Res Commun. 2009 Feb 13;379(3):795-8
pubmed: 19059205
Mol Nutr Food Res. 2007 Jul;51(7):888-98
pubmed: 17579897
Metabolism. 2006 Mar;55(3):292-9
pubmed: 16483871
Planta Med. 2012 Dec;78(18):1949-56
pubmed: 23136063
J Agric Food Chem. 2010 Oct 13;58(19):10793-8
pubmed: 20828195
J Ethnopharmacol. 2008 Oct 28;119(3):559-74
pubmed: 18620038
Bioorg Med Chem. 2008 Feb 1;16(3):1460-73
pubmed: 17983753
S Afr Med J. 2003 May;93(5):359-61
pubmed: 12830599
Pharmaceutics. 2020 May 28;12(6):
pubmed: 32481565
Phytother Res. 2000 Nov;14(7):534-7
pubmed: 11054844
J Ethnopharmacol. 2006 Apr 21;105(1-2):84-8
pubmed: 16309865
Antioxidants (Basel). 2022 Sep 27;11(10):
pubmed: 36290632
Biomed Pharmacother. 2022 Jun;150:113054
pubmed: 35658225
BMB Rep. 2014 Aug;47(8):433-8
pubmed: 24286323
Endocr Metab Immune Disord Drug Targets. 2019;19(6):826-837
pubmed: 30727937
Drug Des Devel Ther. 2015 May 28;9:2793-800
pubmed: 26060396
Steroids. 2019 Jan;141:30-35
pubmed: 30444979
Fitoterapia. 2009 Mar;80(2):123-6
pubmed: 19105977
Org Biomol Chem. 2005 Aug 21;3(16):3059-65
pubmed: 16186940
Arq Bras Cardiol. 2017 Nov;109(5):475-482
pubmed: 29267628
Phytochemistry. 2021 Jul;187:112759
pubmed: 33839518
Molecules. 2021 Apr 16;26(8):
pubmed: 33923374
J Agric Food Chem. 2010 Jan 27;58(2):1165-73
pubmed: 20025271